Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 1

Status

Completed 2Withdrawn 1

Sponsor Class

INDUSTRY 2NIH 1

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 3

Conditions

Adenomatous Polyposis Coli 3Colorectal Neoplasms 2Stomach Neoplasms 1Gastritis, Atrophic 1Esophageal Neoplasms 1Colonic Polyps 1

Interventions

Celecoxib 7Biopsy 5Sulindac 4Specimen Handling 3Eflornithine 3Curcumin 3guselkumab 2Ursodeoxycholic Acid 2Surveys and Questionnaires 2Sirolimus 2Sigmoidoscopy 2Gastroscopy 2Erythromycin 2Erlotinib Hydrochloride 2Endoscopy, Gastrointestinal 2Endoscopy, Digestive System 2Endoscopy 2Colonoscopy 2trifluridine tipiracil drug combination 1rofecoxib 1obeticholic acid 1Thiamine 1Surgical Procedures, Operative 1Suppositories 1Probiotics 1Polymorphism, Single-Stranded Conformational 1Polymerase Chain Reaction 1Pharmaceutical Preparations 1Oxaliplatin 1Nivolumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Adenomatous Polyposis Coli × Eflornithine × Gastrointestinal × Clear all
NCT01483144 2021-06-08

Trial of Eflornithine Plus Sulindac in Patients With Familial Adenomatous Polyposis (FAP)

Cancer Prevention Pharmaceuticals, Inc.

Phase 3 Completed
171 enrolled 13 charts
Gastrointestinal

Adenomatous Polyposis Coli

NCT00033371 2020-09-29

Celecoxib With or Without Eflornithine in Preventing Colorectal Cancer in Patients With Familial Adenomatous Polyposis

National Cancer Institute (NCI)

Phase 2 Completed
205 enrolled 16 charts
Gastrointestinal

Adenomatous Polyposis Coli, Colorectal Neoplasms

NCT01245816 2015-04-24

A Trial of Low Dose Sulindac Combined With Eflornithine in Patients With Familial Adenomatous Polyposis (FAP)

Cancer Prevention Pharmaceuticals, Inc.

Phase 3 Withdrawn
Gastrointestinal

Colonic Polyps, Adenomatous Polyposis Coli

Data powered by HemOnc (CC BY 4.0) Colophon âš¡